Terminated Trial Highlights Need for Digital Health Solutions in Lung Cancer Care — What Clinicians Can Learn

References

1. 1.Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., ... & Imamura, F. (2017). Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New England Journal of Medicine, 377(20), 1919-1929. https://doi.org/10.1056/NEJMoa1709937
2. 2.Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., & Schrag, D. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 318(2), 197-198. https://doi.org/10.1001/jama.2017.7156
3. 3.Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., ... & Choy, H. (2015). Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer. Journal of Clinical Oncology, 33(17), 1958-1965. https://doi.org/10.1200/JCO.2014.58.3038
4. 4.Granger, C. L., McDonald, C. F., Berney, S., Chao, C., & Denehy, L. (2011). Exercise intervention to improve exercise capacity and health related quality of life for patients with non-small cell lung cancer. Cochrane Database of Systematic Reviews, (2). https://doi.org/10.1002/14651858.CD009285
5. 5.NRG Oncology. (2024). Activity Monitoring to Improve Patient Care During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC). ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04878952
6. 6.Patel, M. S., Asch, D. A., & Volpp, K. G. (2015). Wearable devices as facilitators, not drivers, of health behavior change. JAMA, 313(5), 459-460. https://doi.org/10.1001/jama.2014.14781
7. 7.Rudin, C. M., Brambilla, E., Faivre-Finn, C., & Sage, J. (2021). Small-cell lung cancer. Nature Reviews Disease Primers, 7(1), 3. https://doi.org/10.1038/s41572-020-00235-0